MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
7.76
-0.37 (-4.55%)
At close: Mar 25, 2025, 4:00 PM
7.75
-0.01 (-0.13%)
After-hours: Mar 25, 2025, 5:50 PM EST
MBX Biosciences Employees
MBX Biosciences had 27 employees as of December 31, 2023.
Employees
27
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,293,407
Market Cap
259.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBX News
- 8 days ago - MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 20 days ago - MBX Biosciences Announces Additions to Leadership Team - GlobeNewsWire
- 22 days ago - MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - GlobeNewsWire
- 5 weeks ago - MBX Biosciences to Participate in March Investor Conferences - GlobeNewsWire
- 2 months ago - MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia - GlobeNewsWire
- 4 months ago - MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia - GlobeNewsWire
- 5 months ago - MBX Biosciences to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 6 months ago - MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - GlobeNewsWire